TAC新辅助化疗方案联合保乳术治疗Ⅱ期乳腺癌患者的效果  

Effects of TAC neoadjuvant chemotherapy combined with breast-conserving surgery in treatment of stageⅡbreast cancer

作　　者：王伟 许静 马昕 WANG Wei;XU Jing;MA Xin(Department of Tumor Radiotherapy of Liangzhou Hospital,Wuwei 733000 Gansu,China)

机构地区：[1]武威市凉州医院肿瘤放射治疗科,甘肃武威733000

出　　处：《中国民康医学》2024年第20期59-61,71,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察TAC新辅助化疗方案联合保乳术治疗Ⅱ期乳腺癌患者的效果。方法:选取2020年2月至2022年2月该院收治的80例Ⅱ期乳腺癌患者进行前瞻性研究,按照随机数字表法将其分为对照组和研究组各40例。对照组采用保乳术治疗,研究组在对照组基础上联合TAC新辅助化疗方案治疗,比较两组保乳成功率,治疗前后肿瘤标志物[血清血管内皮生长因子(VEGF)、糖类抗原125(CA125)、糖类抗原15-3(CA15-3)、癌胚抗原(CEA)]水平、健康状态[卡氏功能状态评分表(KPS)]评分、生命质量[乳腺癌患者生命质量测定量表(FACT-B)]评分,以及术后14 d并发症发生率。结果:研究组保乳成功率为92.50%(37/40),高于对照组的75.00%(30/40),差异有统计学意义(P<0.05);治疗后,研究组CEA、VEGF、CA125、CA15-3水平均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组KPS、FACT-B评分均高于对照组,差异有统计学意义(P<0.05);两组并发症发生率比较,差异无统计学意义(P>0.05)。结论:TAC新辅助化疗方案联合保乳术治疗Ⅱ期乳腺癌患者可提高保乳成功率、KPS评分和FACT-B评分,降低肿瘤标志物水平,效果优于单纯保乳术治疗。Objective:To analyze effects of TAC neoadjuvant chemotherapy combined with breast-conserving surgery in treatment of stageⅡbreast cancer.Methods:A prospective study was conducted on 80 patients with stageⅡbreast cancer admitted to the hospital from February 2020 to February 2022.According to the random number table method,they were divided into control group and study group,40 cases in each group.The control group was treated with breast-conserving surgery,while the study group was treated with TAC neoadjuvant chemotherapy combined with breast-conserving surgery.The success rate of breast-conserving,the levels of tumor markers[serum vascular endothelial growth factor(VEGF),carbohydrate antigen 125(CA125),carbohydrate antigen 15-3(CA15-3),carcinoembryonic antigen(CEA)],the health status[Karnofsky performance status(KPS)]score,the quality of life[functional assessment of cancer therapy-breast(FACT-B)]score,and the incidence of complications at 14 days after the surgery were compared between the two groups before and after the treatment.Results:The success rate of breast-conserving in the study group was 92.50%(37/40),which was higher than 75.00%(30/40)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CEA,VEGF,CA125 and CA15-3 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the KPS and FACT-B scores of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusions:TAC neoadjuvant chemotherapy combined with breast-conserving surgery in the treatment of the stageⅡbreast cancer patients can improve the success rate of breast-conserving surgery,the KPS scores and the FACT-B scores,and reduce the levels of tumor markers.Moreover,it is superior to simple breast-conserving surgery.

关 键 词：Ⅱ期乳腺癌 新辅助化疗 TAC方案 保乳术 肿瘤标志物 生命质量 健康状态 

分 类 号：R737.9[医药卫生—肿瘤]